Rapamycin for the treatment of lymphangioleiomyomatosis
AssigneeAI Therapeutics, Inc.
InventorsHenri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
Claims19
A pharmaceutical dry powder composition for pulmonary delivery comprising microparticles of sirolimus, particles of a carrier, and one or more optional excipients, wherein the microparticles of sirolimus have a mean diameter of from 1 to 5 microns and the sirolimus is the only therapeutic agent in the composition.
Dependencies are inferred from the claim text.